Two-way Combinated Chemotheraphy for 44 Cases of stage Ⅲ Epithelial Ovary Carcinoma
-
摘要: 目的:采取双途径化疗的模式作为Ⅲ期卵巢上皮癌减瘤术后的辅助治疗,并与常规术后辅助化疗相比观察疗效。方法:92例Ⅲ期卵巢上皮癌患者随机分为A组(双途径化疗组44例)和B组(对照组,常规静脉化疗48例)进行治疗。结果:A组和B组的1年生存率(OS)为90.9%和83.3%;3年生存率为80.0%和40.0%,两组比较有显著性差异(P<0.05)。A组和B组的1年无进展生存率(DFS)为81.8%和50.0%;3年无进展生存率为60.0%和20.0%,两组比较均有显著性差异(P<0.05)。结论:双途径化疗是Ⅲ期卵巢上皮癌患者减瘤术后较为理想的辅助治疗模式。Abstract: Objective : To study the result of two -way combinated chemotheraphy for epithelialovary carcinoma of stage Ⅲ. Methods : A total of 92 cases with epithelial ovary carcinoma at stage Ⅲwere randomized into two groups. The patients received two-way chemotheraphy in group A (46 cases)and received routine intravenous chemotheraphy in group B (44 cases). Results : The 1- and N -year survial rate of the two groups was 90.9% vs 83.3% (P >0.05) and 80.0% Vs 40.0% (P<0.05),respectively; the 1- and 3-year disease-frdee survial rate of the two groups was 81.8% vs 50.0% (P<0.05) and 60.0% vs 20.0% (P<0.05), respectively. Conclusion : These results demonstrate that the two-way chemotheraphy is obviously better than the adjuvant chemotheraphy for the patients with stage Ⅲ epithelial ovary carcinoma.
-
-
[1] 1 王淑珍.实用妇产科学[M].北京:人民卫生出版社,1991.686-721.
2 孙燕.肿瘤内科学[M].北京:人民卫生出版社,2001.711-714.
3 Thigpen JT,Vance RB,Khansur T.Second-Line chemotheraphy for recurrent carcinoma of the ovary[J].Cancer,1993.1559.
4 黄洁夫,龙启才,肖建初.新药物手册[M].福州:福建科学技术出版社,2001.763.
5 孙燕,周际昌.临床肿瘤内科手册[M].北京:人民卫生出版社,1996.353-355.
6 王怀瑾,刘艳娥,陈骏.吡柔比星联合化疗方案治疗晚期恶性肿瘤的临床观察[J].中国肿瘤临床,1999,(09):714-715.
7 成卫,郑秀立.腹腔内化疗[J].癌症,1999,(03):344-346.
8 Sugarbaker PH.Peritoneal Carcinomatosis:natural history and tational therapctic intervention susing intrapertioneal chemotheraphy[J].Cancer Treatment and Research,1996.149-168.
9 Shigonasa K,Ryuidai H,Miohio M.Prophylactic theraphy for peritoneal recurrence of gastric cancer by CHP P with MMC[J].Cancer,1998.232.
10 周彦杰,陈亦乐,吴晓英.22例卵巢癌术中行腹腔热灌注化疗其游离癌细胞变化的观察[J].中国肿瘤临床,2004,(17):965-967.
计量
- 文章访问数: 4
- HTML全文浏览量: 0
- PDF下载量: 1
下载:
